Lyric/Metadherin (2F11C3) Mouse mAb





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H Mk	Sensitivity: Endogenous	MW (kDa): 65, 75	Source/Isotype: Mouse IgG1	UniProt ID: #Q86UE4	Entrez-Gene Id: 92140		
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sen	sitivity	Lyric/Metadherin (2F11C3) Mouse mAb detects endogenous levels of total lyric/metadherin protein.						
Source / Purific	cation		Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human lyric/metadherin protein.					
Background		Lyric/AEG-1 (Astrocyte Elevated Gene 1)/MTDH (Metadherin) was identified as a tight junction (TJ) proteins in polarized epithelium (1).						
		Differential subcellular localization and overexpression of Lyric/AEG-1/MTDH has been seen in multiple human cancers. Lyric/AEG-1/MTDH is involved in signaling pathways related to various cellular functions including proliferation and apoptosis/survival, and its alteration in cancer is associated with poor prognosis (reviewed in 2). In breast cancer, increased Lyric/AEG-1/MTDH may confer increased chemoresistance as well as metastasis (3,4). Lyric/AEG-1/MTDH expression is important in signaling and disease progression of hepatocellular carcinoma (HCC) (5) and glioblastoma multiforme (GBM) (6).						
Background Re	eferences	1. Britt, D.E. et al. (2004) <i>Exp Cell Res</i> 300, 134-48. 2. Hu, G. et al. (2009) <i>Clin Cancer Res</i> 15, 5615-20. 3. Brown, D.M. and Ruoslahti, E. (2004) <i>Cancer Cell</i> 5, 365-74. 4. Hu, G. et al. (2009) <i>Cancer Cell</i> 15, 9-20. 5. Yoo, B.K. et al. (2009) <i>J Clin Invest</i> 119, 465-77. 6. Emdad, L. et al. (2010) <i>Mol Cancer Ther</i> 9, 79-88.						
Species Reactiv	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).						
Western Blot B	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ey	W: Western Blotting IP: Immunoprecipitation						
Cross-Reactivit	у Кеу	H: Human Mk: Monkey						
Trademarks an	d Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		All other trademarks an more information.	ademarks are the property of their respective owners. Visit cellsignal.com/trademarks for nation.					
Limited Uses		the following terms ap terms and conditions t	therwise expressly agreed in a writing signed by a legally authorized representative of CST, ng terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's conditions that are in addition to, or different from, those contained herein, unless accepted in writing by a legally authorized representative of CST, are rejected and are of no fect.					
		approved, cleared, or li purpose. Customer sha	icensed by the FDA all not use any Pro	se Only or a similar labe or other regulatory fore duct for any diagnostic o g statement. Products so	eign or domestic en or therapeutic purp	itity, for any ose, or otherwise in		

Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.